Furthermore, CB1 activation was involved in the pathogenesis of obesity-related hypertriglyceridemia which underscored the potential efficacy of CB1 antagonists in treating metabolic disease [68]. This evidence concerns the gene CNR1 and hypertriglyceridemia.